Occult HBV infection in Morocco: From chronic hepatitis to hepatocellular carcinoma

Liver International

Volumn 34, Issue 6, 2014, Pages

  Kitab, Bouchra ^a   Ezzikouri, Sayeh ^a   Alaoui, Rhimo ^b   Nadir, Salwa ^b   Badre, Wafaa ^b   Trepo, Christian ^c   Chemin, Isabelle ^c   Benjelloun, Soumaya ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Chronic HCV infection; Cryptogenic hepatitis; Hepatitis B virus; Hepatocellular carcinoma; Occult HBV infection

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; HYBRIDIZATION; LIVER; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOROCCO; OCCULT HEPATITIS B VIRUS INFECTION; PREVALENCE; RISK FACTOR; SOUTHERN BLOTTING; VIRUS LOAD; AGE; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; GENETICS; HEPATITIS B, CHRONIC; HEPATITIS C; IMMUNOLOGY; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TIME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOROCCO; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84902536677     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12482     Document Type: Article

References (38)

1. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
2. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001; 34: 194-203.
3. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34: S15-21.
4. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
5. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25: 142-63.
6. Gutierrez-Garcia ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 1538-42.
7. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol 2010; 58: 254-7.
8. Kannangai R, Vivekanandan P, Netski D, et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 2007; 39: 101-5.
9. Selim HS, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. Eur J Intern Med 2011; 22: 187-90.
10. Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis 2013; 45: 238-44.
11. Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 2010; 55: 3328-35.
12. Benjelloun S, Bahbouhi B, Sekkat S, et al. Anti-HCV seroprevalence and risk factors of hepatitis C virus infection in Moroccan population groups. Res Virol 1996; 147: 247-55.
13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. the METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
14. Chemin I, Zoulim F, Merle P, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001; 34: 447-54.
15. Uchida T, Kaneita Y, Gotoh K, et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol 1997; 52: 399-405.
16. Gheit T, Sekkat S, Cova L, et al. Experimental transfection of Macaca sylvanus with cloned human hepatitis B virus. J Gen Virol 2002; 83: 1645-9.
17. Brahim I, Akil A, el Mtairag M, et al. Morocco underwent a drift of circulating hepatitis C virus subtypes in recent decades. Arch Virol 2012; 157: 515-20.
18. Sagnelli E, Imparato M, Coppola N, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008; 80: 1547-53.
19. Mrani S, Chemin I, Menouar K, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007; 79: 1075-81.
20. Halima SB, Bahri O, Maamouri N, et al. Serological and molecular expression of Hepatitis B infection in patients with chronic Hepatitis C from Tunisia North Africa. Virol J 2010; 7: 229.
21. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
22. Wong DK, Huang FY, Lai CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-36.
23. Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009; 58: 383-8.
24. Baha W, Foullous A, Dersi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health 2013; 13: 50.
25. Duseja A, Sharma S, Subramanian PG, et al. Occult hepatitis B virus (HBV) infection in healthy blood donors. Indian J Pathol Microbiol 2003; 46: 690-2.
26. Sofian M, Aghakhani A, Izadi N, et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010; 14: e308-10.
27. Dumoulin FL, von dem Bussche A, Li J, et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology 2003; 305: 260-6.
28. Schuttler CG, Fiedler N, Schmidt K, et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37: 855-62.
29. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009; 50: 46-55.
30. Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009; 51: 446-57.
31. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
32. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16: 437-43.
33. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013; 59: 696-700.
34. Shi Y, Wu YH, Wu W, et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012; 32: 231-40.
35. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.
36. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286: 52-9.
37. Adachi S, Shibuya A, Miura Y, et al. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 2008; 43: 849-56.
38. Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146: 649-56.